Illumina shares surged 12.8% post-earnings after the company reported first quarter revenue, margins, and EPS all above guidance, alongside a raise to full-year 2026 guidance. The upside was driven by outperformance in the clinical sequencing business, Rest of World growth, and higher-than-expected operating margins amid a challenging cost environment.

• Q1 results came in above guidance for revenue, margin, and EPS; management cited disciplined execution and clinical market strength.
• Rest of World organic sales grew 3.5%, surpassing the high end of guidance, led by 7% growth in sequencing consumables and 20% growth in clinical applications.
• Over 80 NovaSeq X placements were completed, up 20 units year over year, with increased adoption in both clinical and nonclinical markets.
• Margins for the quarter came in approximately 150 basis points above guidance, driven by strong revenue and focused expense management.
• Full-year 2026 guidance was raised to reflect Q1 outperformance and expectations for continued growth, particularly in the clinical segment, amid ongoing innovation such as the launch of TruPath and new platform enhancements.